Responsible Care
02-dec-2009
Ontwikkeling van een nieuwe BiTE antistof voor de behandeling van harde tumors:
Bayer Schering Pharma werkt samen met Micromet op een nieuwe aanpak van kankertherapie
Bayer Schering Pharma AG, en Allemagne, Germany, will develop a new BiTE antibody for the treatment
of solid tumors in collaboration with the biopharmaceutical company Micromet, Inc. In January 2009,
both companies had entered into an option, license and collaboration agreement. By exercising the
option now, Bayer Schering Pharma has triggered a joint collaboration on the development of the
BiTE antibody against an undisclosed solid tumor target through the completion of Phase I clinical
trials, at which point Bayer will assume full control of the further development and
commercialization of the antibody. BiTE antibodies are designed to direct the body's
cell-destroying T cells against tumor cells, and represent a new therapeutic approach to cancer
therapy.
Ontwikkeling van een nieuwe BiTE antistof voor de behandeling van harde tumors:
Bayer Schering Pharma werkt samen met Micromet op een nieuwe aanpak van kankertherapie